SLC9A1 and breast cancer: Wang X.’s group investigated the impact of adipose-derived small EVs on response to therapy and found out that ASC-exos carrying miR-1236 increased response to cisplatin in BC cells by suppressing Solute Carrier Family 9 Member A1 (SLC9A1), an isoform of sodium–hydrogen antiporter, and the Wnt/β-Catenin Signaling [75].